A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

Centro Oncologico Korben ( Site 0254), CABA, Buenos Aires, Argentina

Instituto de Investigaciones Clinicas Mar del Plata ( Site 0250), Mar del Plata, Buenos Aires, Argentina

Centro Privado de RMI Río Cuarto S.A. II ( Site 0255), Río Cuarto, Córdoba Province, Argentina

Sanatorio Parque ( Site 0251), Rosario, Santa Fe Province, Argentina

Centro Oncológico Riojano Integral ( Site 0256), La Rioja, Argentina

Macquarie University ( Site 2700), Macquarie University, New South Wales, Australia

Masarykuv onkologicky ustav ( Site 0903), Brno, Brno-mesto, Czechia

Fakultni nemocnice v Motole ( Site 0900), Prague, Czechia

Herlev Hospital ( Site 1002), Herlev, Capital Region, Denmark

Aarhus Universitetshospital, Skejby ( Site 1001), Aarhus, Central Jutland, Denmark

Metropolitan Hospital ( Site 1402), Athens, Attica, Greece

Rambam Health Care Campus ( Site 1600), Haifa, Israel

Rabin Medical Center ( Site 1602), Petah Tikva, Israel

Sheba Medical Center ( Site 1601), Ramat Gan, Israel

Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 1900), Amsterdam, North Holland, Netherlands

Haga Ziekenhuis locatie Leyweg ( Site 1906), The Hague, South Holland, Netherlands

AIDPORT Sp. z o.o. ( Site 2118), Skórzewo, Greater Poland Voivodeship, Poland

MTZ Clinical Research Powered by Pratia ( Site 2107), Warsaw, Masovian Voivodeship, Poland

Severance Hospital, Yonsei University Health System ( Site 2903), Seoul, South Korea

Asan Medical Center ( Site 2901), Seoul, South Korea

Samsung Medical Center ( Site 2902), Seoul, South Korea

Institut Català d'Oncologia - L'Hospitalet ( Site 2305), L'Hospitalet de Llobregat, Barcelona, Spain

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 2301), Madrid, Madrid, Comunidad de, Spain

Hospital Insular de Gran Canaria ( Site 2308), Las Palmas, Spain

Hospital Universitario 12 de Octubre ( Site 2300), Madrid, Spain